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Abstract: Aberrant protein oligomerization is an important pathogenetic process in vivo. In Alzheimer’s
disease (AD), the amyloid â-protein (Aâ) forms neurotoxic oligomers. The predominant in vivo Aâ alloforms,
Aâ40 and Aâ42, have distinct oligomerization pathways. Aâ42 monomers oligomerize into pentamer/hexamer
units (paranuclei) which self-associate to form larger oligomers. Aâ40 does not form these paranuclei, a
fact which may explain the particularly strong linkage of Aâ42 with AD. Here, we sought to determine the
structural elements controlling paranucleus formation as a first step toward the development of strategies
for treating AD. Because oxidation of Met35 is associated with altered Aâ assembly, we examined the role
of Met35 in controlling Aâ oligomerization. Oxidation of Met35 in Aâ42 blocked paranucleus formation and
produced oligomers indistinguishable in size and morphology from those produced by Aâ40. Systematic
structural alterations of the Cç35-substituent group revealed that its electronic nature, rather than its size
(van der Waals volume), was the factor controlling oligomerization pathway choice. Preventing assembly
of toxic Aâ42 paranuclei through selective oxidation of Met35 thus represents a potential therapeutic approach
for AD.
Introduction
Amyloid â-protein (Aâ) is the main proteinaceous component
of the amyloid plaques found in the brains of Alzheimer’s
disease (AD) patients.1,2 Neuritic plaques, pathognomonic
features of AD, contain abundant fibrils formed from Aâ. These
fibrils have been found to be neurotoxic in vivo and in vitro.3-5
Recent studies of structure-activity relationships among fibril
assembly intermediates have revealed that many intermediates
are neurotoxic, including dimers and trimers,6 Aâ-derived
diffusible ligands (ADDLs),7 and protofibrils.8,9 These oligomers
may, in fact, be the proximal effectors of neuropathogenesis in
AD.10-12 This new insight into the assembly and biological
activity of fibril precursors suggests that therapeutic strategies
may need to target oligomeric assemblies. To facilitate the
development of these strategies, an understanding of the
mechanisms controlling the formation of oligomeric Aâ as-
semblies is necessary.
The predominant forms of Aâ found in brains of AD patients
are 40 and 42 amino acids long (designated Aâ40 and Aâ42,
respectively).13,14 Despite the small primary structure difference
between Aâ40 and Aâ42, i.e., the dipeptide Ile41-Ala42, the
clinical impact and biophysical behavior of the two Aâ alloforms
are distinct. Aâ40 and Aâ42 exist in the plasma and cerebrospi-
nal fluid at a concentration ratio of 10:1, respectively, yet
Aâ42 is deposited first during the development of AD 15,16 and
is more neurotoxic than Aâ40.17,18 Alloform-specific patterns
of amyloid deposition are observed. Aâ42 is the predominant
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component in parenchymal plaques, whereas Aâ40 is the
predominant component in vascular deposits.19,20 An increase
in the Aâ42/Aâ40 ratio is associated with early onset familial
AD.21,22 Oligomeric Aâ42 has been shown to be toxic to
neuronal cells at nanomolar levels in vitro,7,23-29 whereas Aâ40
oligomers are significantly less toxic.18,30 In addition, Aâ42 has
been shown to form fibrils substantially faster than Aâ40.31,32
Recently, we demonstrated that the early assembly of Aâ42
involves formation of pentamer/hexamer units termed para-
nuclei.33 Following their formation, paranuclei self-associate into
larger oligomers, which appear to give rise to protofibrils.33
Paranucleus formation is the earliest observable Aâ42 assembly
event. Early Aâ40 assembly produces an equilibrium mixture
of monomer, dimer, trimer, and tetramer.34 Assemblies in this
mixture are largely amorphous, in contrast to the quasiglobular
paranuclei observed in Aâ42 preparations.33 These biophysical
differences between Aâ40 and Aâ42 are likely to underlie the
distinct biological behaviors of the two peptides. Therapeutic
agents capable of directing Aâ42 down oligomerization path-
ways akin to that of Aâ40, i.e., delaying or inhibiting para-
nucleus formation and self-association, thus could be of clinical
value.
It has been postulated that Met35 contributes to the neurotoxic
activity of Aâ. In particular, oxidation of Met35 to the corre-
sponding sulfoxide (Met(O)35) has been suggested to be involved
in Aâ-induced oxidative damage.35,36 However, a confusing
observation is that the toxicity of Aâ increases with assembly
of the monomeric peptide into oligomers and fibrils, but its
oxidative power is highest for monomers and decreases with
assembly.37 In addition, solution NMR studies of reduced and
oxidized Aâ40 and Aâ42 have shown little conformational
difference among the four peptides,38 suggesting that the effect
of Met35 on the biological activity of Aâ is exerted in the
assembled state, rather than in the monomeric state. [Met-
(O)35]Aâ has been reported to display both accelerated39,40 and
delayed41 fibrillogenesis rates relative to wild type (WT) Aâ.
The biological implications of these data are unclear. Recent
reports have shown that formation of small oligomers by Aâ4042
and of protofibrils by Aâ4043 and Aâ4244 is delayed upon Met35
oxidation. If oligomeric assemblies, rather than fibrils, are the
key effectors of neurotoxicity in AD, then differences in
assembly kinetics may not underlie the differences in biological
activity between the reduced (native) and oxidized Aâ forms.
Rather, the distinct neurotoxic activity of different Aâ alloforms
may reflect qualitative differences such as formation or stabi-
lization of particular oligomeric assemblies. Here, we examined
the effect of Met35 oxidation on the oligomer size distribution
of Aâ40 and Aâ42 using the technique of Photoinduced Cross-
linking of Unmodified Proteins (PICUP).45,46 PICUP provides
the means to identify and quantitate small, metastable oligomers.
These analyses are difficult using other biochemical or bio-
physical methods.34 The current study reveals that oxidation of
Met35 transforms the oligomer size distribution of Aâ42 into
one that is indistinguishable from that of Aâ40, suggesting a
key role for Met35 in the formation of paranuclei and in the
control of oligomerization pathway choice.
Results
Characterization of the Oligomer Size Distributions of
Reduced and Oxidized Aâ40 and Aâ42. To determine the
effects of oxidation of Met35 to Met-sulfoxide [Met(O)35] on
the oligomer size distributions of Aâ40 and Aâ42, low
molecular weight (LMW47) fractions of the reduced and oxidized
peptides were isolated using size exclusion chromatography
(SEC) and immediately cross-linked. SDS-PAGE analysis of
cross-linked wild-type (WT) and oxidized Aâ40 revealed little
difference between the oligomer size distributions (Figure 1A,
lanes 1 and 3). Both distributions showed comparable abun-
dances of monomer through tetramer, followed by a sharp
decrease of the abundances of pentamer through heptamer, as
described previously.34 The distribution of WT Aâ42 comprised
three groups of oligomers (Figure 1A, lane 2): monomer
through trimer, displaying decreasing intensity with increasing
oligomer order; a Gaussian-like distribution between tetramer
and octamer, with a maximum at pentamer and hexamer; and
oligomers of Mr  30-60 kDa showing intensity maxima
consistent with dodecamer and octadecamer. In contrast, the
oligomer size distribution of [Met(O)35]Aâ42 differed dramati-
cally from that of WT Aâ42. It was, in fact, indistinguishable
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from the oligomer distributions of reduced and oxidized Aâ40
(Figure 1A, lane 4). This result suggested a crucial role for Met35
in the oligomerization of Aâ42, particularly in the formation
of Aâ42 paranuclei. Moreover, the data demonstrated that the
particular interactions leading to the oligomer size distribution
observed for WT Aâ42, which of necessity involve Ile41 and
Ala42,33,48 were abolished by oxidation of Met35 to the corre-
sponding sulfoxide.
In principle, the differences in the oligomerization patterns
among Aâ42 and oxidized Aâ42 or Aâ40 may reflect solubility
differences rather than distinct oligomerization behavior. If so,
[Met(O)35]Aâ42 and Aâ40, at higher concentrations, might form
paranuclei. To address this question, we compared the oligomer
size distributions of Aâ40, Aâ42, and [Met(O)35]Aâ42 at
nominal concentrations of 30 and 300 íM (Figure 1B). For all
three alloforms, the oligomer size distributions obtained at 30
and 300 íM were essentially identical, demonstrating that the
effect of oxidation on the oligomerization pattern was concen-
tration-independent over this range of concentration, at a
minimum.
Elucidation of Structural Elements at Cç35 which Control
Aâ42 Paranucleus Formation. To determine the structural
elements of residue 35 which affect paranucleus formation, three
additional modifications were examined, oxidation of Met35 to
Met-sulfone [Met(O2)35] and substitutions by norleucine (Nle)
and homoleucine (Hle). To compare the relative influence of
electrostatic and steric forces, the dipole moments and van der
Waals volumes of side chain portions beyond the ç-methylene
were computed for each of the residues used (Table 1).
Oxidation of Met to Met(O2) is similar to oxidation to Met(O)
in that it increases both the size and the polarity of the side
chain (Table 1). Substitution of Met by Nle maintains the size
and decreases the polarity of the side chain, whereas substitution
by Hle increases the size and decreases the polarity (Table 1).
SEC-isolated LMW Aâ42 containing Met(O2), Nle, or Hle
in position 35 were cross-linked and analyzed by SDS-PAGE.
The Aâ40 counterparts of these peptides were used as controls.
The effect of oxidation of Met to Met(O2) was identical to that
of oxidation to Met(O) (cf., Figure 1A, lane 4 with lane 6). In
fact, [Met(O2)35]Aâ42 yielded a distribution indistinguishable
from those of [Met(O)35]Aâ42 and all of the Aâ40 analogues
examined (Figure 1A). By contrast, the distributions of
[Nle35]Aâ42 and [Hle35]Aâ42 were qualitatively similar to that
of WT Aâ42 (cf., Figure 1A, lanes 2, 8, and 10). They contained
the same three groups of oligomers and the predominant cross-
linking products were pentamer/hexamer. The relative abun-
dance of the third oligomer group (30-60 kDa) was decreased
in the distributions of the Nle and Hle analogues, relative to
WT Aâ42. The sulfur atom in residue 35 thus was not required
for the formation of paranuclei, but the Met side chain facilitated
the self-association of paranuclei more than the all-hydrocarbon
side chains. The data suggest that the unique oligomer size
(48) Bitan, G.; Vollers, S. S.; Teplow, D. B. J. Biol. Chem. 2003, 278, 34 882-
34 889.
Figure 1. Effects of residue 35 side-chain structure and peptide concentra-
tion on Aâ oligomerization. A) PICUP was performed on SEC-isolated
LMW Aâ40 and Aâ42 analogues containing the modifications Met35 f
Met(O), Met35 f Met(O2), Met35 f Nle, and Met35 f Hle. WT Aâ40 and
Aâ42 were used as controls. Following cross-linking, the products were
analyzed by SDS-PAGE and silver staining. Positions of molecular weight
markers are shown on the left. The gel is representative of each of 3
independent experiments. B) PICUP was applied to freshly dissolved Aâ40,
Aâ42, and [Met(O)35]Aâ42 at nominal concentrations of 30 and 300 íM.
Each peptide first was dissolved in water at a nominal concentration of 4
mg/mL. The pH then was adjusted to 10 by addition of 1N NaOH, after
which 20 mM sodium phosphate, pH 7.4, was added to yield a final nominal
peptide concentration of 300 íM. The solutions were sonicated for 1 min.
Aliquots from these solutions were diluted 10-fold in 10 mM sodium
phosphate, pH 7.4, to produce the 30 íM solutions. Following cross-linking,
the products were analyzed by SDS-PAGE and silver staining. The volumes
loaded were adjusted so that equal amounts of protein were loaded in each
lane. Positions of molecular weight markers are shown on the left. The gel
is representative of each of 3 independent experiments.
Table 1. Calculated Dipole Moments and van der Waals Volumes
for Cç35-Substituent
a Values calculated for the chemical group X attached to the ç-methylene
of residue 35.
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distribution of Aâ42 requires the hydrophobic, rather than the
steric characteristics of Met35. Thus, although the van der Waals
volume of the Hle side chain is larger that those of Met(O) or
Met(O2) (Table 1), the oligomer distribution of [Hle35]Aâ42
was qualitatively similar to that of the WT peptide. The change
in polarity, rather than the change in size, of the Met side chain
thus appears responsible for the major alteration of the Aâ42
oligomer size distribution following oxidation. The oxidation
of Met35 may destabilize paranuclei due to the increased
energetic cost of desolvating the oxidized side chain (see
Discussion).
Morphology of Aâ Oligomers. WT LMW Aâ40 and Aâ42
display distinct morphologies immediately following their
preparation.33 LMW Aâ40 is relatively amorphous whereas
LMW Aâ42 produces quasi-globular structures 2-10 nm in
diameter. We determined here the effect of structural modifica-
tions at position 35 on the morphology of LMW Aâ (Figure
2). To do so, LMW fractions of each of the peptides used in
the PICUP experiments were isolated and examined by EM.
The morphology of oxidized Aâ42 resembled that of Aâ40.33
The globular structures observed for WT Aâ42 were not
detected for [Met(O)35]Aâ42 or [Met(O2)35]Aâ42. The change
in the morphology of oxidized Aâ42 relative to WT Aâ42
correlates with the distinct oligomer size distributions observed
for the two peptides.
All Aâ40 analogues produced irregular, prolate aggregates.
Two main classes were observed, one with mean diameter
1-2 nm (Figure 2E white arrow) and the other with mean
diameter 5-10 nm (Figure 2E black arrow). WT and oxidized
Aâ40 produced mainly the thinner structure whereas [Nle35]Aâ40
and [Hle35]Aâ40 produced more of the thicker structures.
Similar structures also were observed for the Aâ42 analogues.
However, WT Aâ42, [Nle35]Aâ42, and [Hle35]Aâ42 also
showed quasi-spherical structures of diameter 5-8 nm, either
alone or associated into small groups. In agreement with the
PICUP data, these quasi-spherical structures were not observed
for [Met(O)35]Aâ42 and [Met(O2)35]Aâ42, or for any of the
Aâ40 analogues, supporting the conclusion that these morphol-
ogies correspond to paranuclei.33
Conformation of LMW Aâ40 and Aâ42 Analogues. We
have shown previously that, immediately following isolation,
LMW Aâ40 and Aâ42 both are predominantly unstructured.33
To assess the conformational effects of side-chain modifications
in position 35, the conformations of all the analogues used in
this study were examined by CD immediately following their
isolation by SEC (The CD spectra are available as Supporting
Information). The predominant secondary structure element for
all alloforms was “random coil.” Small amounts of â-sheet,
â-turn, and R-helix also were observed. The relative amounts
of each structural element were similar for each of the analogues.
These data show, as observed for WT Aâ, that the initial
oligomerization of the analogues containing modifications in
position 35 does not involve substantial conformational rear-
rangement.
Discussion
An important and contentious area in studies of the chemical
biology of Alzheimer’s disease is the role of redox chemistry
and the involvement of Aâ in it. It has been suggested that the
redox state of Met35 is critical in determining the biological
activity of Aâ, yet the mechanism by which this effect is exerted
is not well understood. One hypothesis proposes that oxidation
of Met35, possibly through interaction with transition metal ions,
is directly related to generation of cytotoxic reactive oxygen
species.35,36 Alternatively, oxidative stress may be cellular in
origin and result from the interaction of Aâ with neurons,
microglia, and/or astrocytes.49,50 If so, the assembly state of Aâ
could be vital in controlling these cellular interactions. Con-
sistent with this notion, Met35 oxidation has been reported to
affect Aâ assembly. However, a consensus on precisely how
Met35 does so does not exist. For example, it has been suggested
that [Met(O)35]Aâ forms fibrils faster,39,40 at a similar rate,37,51
or slower38,41 than does WT Aâ. Recent studies have reported
(49) Perry, G.; Nunomura, A.; Hirai, K.; Zhu, X. W.; Perez, M.; Avila, J.;
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Figure 2. Morphologic analysis of LMW Aâ. Aâ40 (Panels A-E) and Aâ42 (panels F-J) containing Met35 (A,F), Met(O)35 (B,G), Met(O2)35 (C,H), Nle35
(D,I), or Hle35 (E,J) were spotted on glow-discharged, carbon-coated grids immediately after isolation by SEC. The samples then were fixed with glutaraldehyde,
stained with uranyl acetate, and examined by EM. Scale bars are 100 nm. The micrographs shown are representative of multiple fields recorded for each of
several grids prepared in at least three independent experiments.
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that oxidation of Met35 retarded the formation of Aâ40 trimer
and tetramer,42 and of Aâ4043 and Aâ4244 protofibrils. In
addition, there is no consensus with regard to the question of
whether oxidation of Met35 attenuates Aâ toxicity.37,52 We show
here that oxidation of Met35 dramatically changes the way in
which Aâ42 oligomerizes. Paranuclei, which recently have been
shown to be characteristic of Aâ42 oligomerization,33 do not
form when Met35 is oxidized. In fact, [Met(O)35]Aâ42 yields
an oligomer size distribution characteristic of Aâ40. Replace-
ment of the sulfur atom by a methylene group, as in [Nle35]Aâ42,
yields a characteristic Aâ42 oligomer size distribution. Substitu-
tion of Met35 by Nle was reported to reduce Aâ fibril-induced
neuronal death.53,54 Studies are now required to determine
whether a similar effect is produced by oligomeric [Nle35]Aâ42.
Our studies of Aâ oligomerization using [Nle35]Aâ42 dem-
onstrate that the sulfur atom is not essential for production of
Aâ42 paranuclei. This conclusion is supported by the observa-
tion that [Hle35]Aâ42 also produces a typical Aâ42-like
oligomer distribution. Hle is as nonpolar as Nle but is
significantly larger than either Nle or Met (Table 1). Therefore,
the polarity, rather than the size, of the residue 35 side-chain
appears to be the key factor controlling oligomerization pathway
choice. One mechanistic explanation for this phenomenon is
that the increased energetic cost of desolvating the oxidized
(polar) side chain of Met(O) or Met(O2) disfavors paranucleus
formation. During paranucleus formation, Met likely participates
in hydrophobic interactions leading to its exclusion from the
solvent-accessible volumesan energetically favorable process
for the relatively nonpolar Met side-chain. This hypothesis is
supported by comparative examination of the energetics of
solvation of dimethyl sulfide (DMS) and dimethyl sulfoxide
(DMSO), compounds corresponding to the side chain groups
beyond the â-methylene in Met and Met(O), respectively (Table
1). Experimental and computational data demonstrate that the
hydration of DMSO is a more favorable process than is the
hydration of DMS. The partial molar enthalpy of DMSO at
infinite dilution in water is -4.33 kcal/mol.55 The solvation free
energy for DMS is 0.15 kcal/mol56 and the solvation enthalpy
is -2.37 kcal/mol.56 The increased solubility of DMSO in water
can be explained by its tendency to act as a hydrogen bond
acceptor.55 In addition, DMSO has a large dipole moment (3.96
D)57 compared to the dipole moment of DMS (1.5 D).57 The
dipole moment of dimethyl sulfone (DMSO2) is even larger
(4.25 D) than that of DMSO. Oxidation of Met to the sulfoxide
or sulfone forms thus produces a substantial dipole moment and
makes the oxidized Met35 a strong hydrogen bond acceptor. This
makes the solvation free energy of the residue substantially
larger than that of the relatively nonpolar Met residue, a change
which would disfavor movement of the side-chain into the apolar
environment of the assembled Aâ oligomer. In support of this
hypothesis, when Aâ42 and [Met(O)35]Aâ42 are mixed in
different ratios and cross-linked, the observed oligomer size
distributions appear to be simple composites of the distribution
of each alloform alone (data not shown). This “titration” of the
oligomer size distribution is consistent with a homotypic peptide
association process in which reduced and oxidized Aâ molecules
do not interact appreciably with each other. Also consistent with
this idea is the recent observation that upon oxidation of Met35,
Aâ no longer interacts with phospholipid vesicles.52
The relationships between the dipoles and van der Waals
volumes corresponding to Met and Met(O2) demonstrate this
effect quantitatively. We assume that the difference in the dipole
moment (3.6 D) between these two side chains is produced
by a point dipole placed at the center of the sulfur atom. The
distance between the center of the sulfur atom and the solvent
exposed surface of the oxygen bound to sulfur is taken to be
3.23 Å.58 This distance is the minimal radius of the spherical
cavity in which the point dipole is placed. The electrostatic
contribution to the free energy of the dipole in water can be
estimated by the classical theory of Onsager59
where RF is the reaction field with which the solvent responds
to the dipole, í is the dipole moment,  is the relative dielectric
constant of the solvent (80 for water), and a is the radius of the
sphere in which the dipole is placed. For the most polar residues,
Met(O) and Met(O2), the aqueous solvation energy (Gelec) is
large, thus the sulfoxide and sulfone functions interact favorably
with solvent water (Table 2). The influence of the difference in
the van der Waals volume can be estimated by evaluating the
work necessary to create a cavity with radius a using a solvent
accessible surface area (SASA) proportionality relation60,61
where ç has the dimensions of a surface tension and ASAS is
the SASA. The results listed in Table 2 were obtained by
choosing 30 cal/(mol Å2) for ç (for alkanes, the typical value
is 20-30 cal/(mol Å2)61). Increasing the volume of Met by
oxidation to Met(O) or Met(O2) leads to a relatively small,
unfavorable energetic cost.
In considering the energetic cost of removing an amino acid
side-chain from an aqueous solvent ( ) 80) and placing it in
an internal, hydrophobic cavity ( ) 4) in an oligomeric form
of a peptide, the “desolvation” energy is the most important
(52) Barnham, K. J.; Ciccotosto, G. D.; Tickler, A. K.; Ali, F. E.; Smith, D. G.;
Williamson, N. A.; Lam, Y. H.; Carrington, D.; Tew, D.; Kocak, G.;
Volitakis, I.; Separovic, F.; Barrow, C. J.; Wade, J. D.; Masters, C. L.;
Cherny, R. A.; Curtain, C. C.; Bush, A. I.; Cappai, R. J. Biol. Chem. 2003.
(53) Varadarajan, S.; Yatin, S.; Kanski, J.; Jahanshahi, F.; Butterfield, D. A.
Brain Res. Bull. 1999, 50, 133-141.
(54) Yatin, S. M.; Varadarajan, S.; Link, C. D.; Butterfield, D. A. Neurobiol.
Aging 1999, 20, 325-330.
(55) Rosenbaum, E. E. Dimethyl Sulfoxide; Marcel Dekker: New York, 1971.
(56) Kubo, M. M.; Gallicchio, E.; Levy, R. M. J. Phys. Chem. B 1977, 101,
10 527-10 534.
(57) Nelson, R. D. J.; Lide, D. R.; Maryott, A. A.; NSRDS-NBS10, 1967.
(58) Strader, M. L.; Feller, S. E. J. Phys. Chem. A 2002, 106, 1074-1080.
(59) Onsager, L. J. Am. Chem. Soc. 1936, 58, 1486-1493.
(60) Lee, B.; Richard, F. M. J. Mol. Biol. 1971, 55, 379-400.
(61) Roux, B. In Computational Biochemistry and Biophysics; Becker, O. M.,
MacKerell, A. D. J., Roux, B., Watanabe, M., Eds.; Marcel Dekker: New
York, 2001.
Table 2. Calculated Side-chain Aqueous Solvation Energya
Residue Gcav Gelec( ) 4) Gelec( ) 80) ¢Gelec
Met 2.85 -0.37 -0.54 0.17
Met(O) 3.05 -3.98 -5.85 1.87
Met(O2) 3.18 -3.86 -5.68 1.82
Nle 2.85 -0.04 -0.06 0.02
Hle 3.30 -0.05 -0.07 0.02
a The cavitation free energy Gcav, the peptide solvation free energy
Gelec( ) 4), the aqueous solvation free energy Gelec( ) 80), and the
“desolvation” energy ¢Gelec were calculated as described in the Discussion.
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factor. This energetic cost is estimated to be
A Met(O) or Met(O2) side-chain partitions preferentially into
the aqueous environment, thus its burial in a less polar oligomer
core, as would occur during paranucleus formation, is unfavor-
able. In contradistinction to solvation effects, the relatively large
excluded volume of the Hle does not significantly disrupt the
formation of small or large oligomers, indicating that steric
effects in the packing about residue 35 are of little significance.
Our observations are consistent with those of Craik and co-
workers,62 who studied Aâ structural changes due to oxidation
of Met35 in monomeric Aâ40 solvated in a water-micelle
environment. In the unoxidized peptide (PDB code 1BA4), the
side chain of Met35 lies on the backbone and does not disrupt
the local helical structure.62 In the oxidized peptide (PDB code
1BA6), the side chain of Met(O)35 is repositioned to make better
contact with the aqueous solvent. The exposure of the methion-
ine sulfoxide residue to solvent disrupts the helical structure
observed in the WT peptide.41 Disruption of Aâ helical structure
by an Ile31 f Pro substitution (a region proximal to Met35) has
been proposed by Butterfield et al. as a mechanism for an
observed suppression of oxidative stress and neurotoxicity.63
Our CD data do not reveal a significant reduction in R-helix
content following Met oxidation, suggesting that solvation
effects, as opposed to secondary structure changes, are the key
determinants of oligomerization state in our experiments.
Previously,33 we demonstrated that paranucleus formation
required an Aâ peptide extending to Ile41. The association of
paranuclei into higher order assemblies required the addition
of Ala42. This second assembly step was facilitated by Thr43 or
by replacement of the C-terminal carboxyl by a carboxamide.48
The data presented here demonstrate that Met35 is involved
directly in formation of Aâ42 paranuclei. It is possible that
paranucleus formation involves direct interaction between Met35
and the Aâ C-terminus, particularly Ile41. Experimental evidence
exists that the C-terminus of monomeric Aâ42 in aqueous
solution does not form a stable structure.38,64 Thus, an interaction
between Met35 and Ile41 likely would be intermolecular in nature
and occur during Aâ42 oligomerization. Alternatively, both
Met35 and Ile41 may be critical in controlling the oligomerization
of Aâ42 but act independently. Further studies are necessary
to evaluate these possibilities.
The observation that the oligomer size distribution and
morphology of oxidized Aâ42 are similar to those of Aâ40
suggests that Met35 oxidation would alter the biological behavior
of the resulting Aâ42 oligomers. Oligomeric Aâ40 is less
neurotoxic than oligomeric Aâ42.18,30 If these distinct neurotoxic
activities correlate with the quaternary structure of Aâ40 and
Aâ42, and oxidation of Met35 reduces the neuronal injury
mediated by Aâ42 oligomers, then oxidizing agents specifically
targeting Met35 within Aâ42 could be valuable therapeutic tools
for AD.
Materials and Methods
Peptides and Reagents. Aâ(1-40), [Met(O)35]Aâ(1-40), [Met-
(O2)35]Aâ(1-40), [Nle35]Aâ(1-40), [Hle35]Aâ(1-40), Aâ(1-42),
[Met(O)35]Aâ(1-42), [Met(O2)35]Aâ(1-42), [Nle35]Aâ(1-42), and
[Hle35]Aâ(1-42) were synthesized by 9-fluorenylmethoxycarbonyl
(FMOC) chemistry, purified by reverse phase HPLC, and characterized
by mass spectroscopy and amino acid analysis (AAA), essentially as
described.65 Mass spectrometry was performed using a ThermoFinnigan
LCQDeca electrospray ionization/ion trap mass spectrometer linked to
a Surveyor HPLC system. Tris(2,2′-bipyridyl)dichlororuthenium(II)
(Ru(Bpy)) and ammonium persulfate (APS) were purchased from Sigma
(Milwaukee, WI). Polyacrylamide gels, buffers, stains, standards, and
equipment for SDS-PAGE were from Invitrogen (Carlsbad, CA).
Isolation of Low Molecular Weight (LMW) Aâ Peptides. LMW
Aâ alloforms were isolated by size exclusion chromatography (SEC),
as described.34 Briefly, 170 íL of a 2 mg/mL peptide solution prepared
in DMSO was fractionated using a 10/30 Superdex 75 HR column
eluted at 0.5 mL/min with 10 mM sodium phosphate, pH 7.4, and the
central portion of the included peak was collected during 30 s. A
10-íL aliquot of each isolate was taken for AAA to determine the
peptide concentration.
Cross-Linking and SDS-PAGE Analysis. Freshly isolated LMW
peptides were immediately subjected to PICUP, as described.34 Briefly,
1 íL of 1 mM Ru(Bpy) and 1 íL of 20 mM APS in 10 mM sodium
phosphate, pH 7.4, were added to 18 íL of freshly isolated LMW
peptide. The mixture was irradiated with visible light, and the reaction
was quenched immediately with 10 íL tricine sample buffer (Invitro-
gen) containing 5% â-mercaptoethanol (â-ME). The cross-linked
oligomer mixtures were analyzed by SDS-PAGE and the intensities
quantified by densitometry, as described.34 The amounts taken for SDS-
PAGE analyses were adjusted according to the peptide concentration
so that equal amounts of protein were loaded in each lane.
Electron Microscopy. SEC-isolated Aâ peptides were used for these
experiments, which were done essentially as described.47 Briefly, 8 íL
of sample were applied to glow-discharged, carbon-coated Formvar
grids (Electron Microscopy Sciences, Washington, PA) and incubated
for 19 min. The solution was gently absorbed using Whatman grade 1
qualitative filter paper. The grid was incubated with 5 íL of 2.5%
glutaraldehyde for 4 min and wicked dry with filter paper. The peptide
then was stained with 5 íL of 1% uranyl acetate (Pfaltz & Bauer, Inc.,
Waterbury, CT) for 3 min. This solution was wicked off, and the grid
was air-dried. Samples were examined using a JEOL CX100 electron
microscope.
Circular Dichroism Spectroscopy. Immediately following isolation
of LMW Aâ, aliquots were placed into a 0.1-cm path length quartz
cell (Hellma, Forest Hills, NY). The spectra were recorded on an Aviv
Model 62A DS spectropolarimeter (Aviv Associates, Lakewood, NJ)
over the wavelength range of 195-260 nm, at 22 °C, as described.66
Computational Methods. The electric dipole moments and the
excluded volumes for Met, Nle, and Hle were calculated using the
version 22 parameter set of the CHARMM program.67 For Met(O),
the parameters proposed by Strander and Feller58 for dimethyl sulfoxide
were used. For the sulfur and the sulfur oxygens in Met(O2), the HF/
6-31g* calculated partial charges for dimethyl sulfone68 were used.
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